Pacira BioSciences (PCRX) stock

Pain management , market cap $1.5B

Treatments for pain and osteoarthritis

Worth $1.5B

Pre-market

$36.47

+0.11%

Close $36.43 +0.03%

As of 9:27 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Excellent

Checks firing

8of 14

Trending up

From 52-week high

-0.6%

under its best in a year

Viatris is buying Pacira BioSciences

The deal is valued at $1.65B.

It still needs regulatory approval.

PCRX's price now follows the deal's terms rather than the business, so Breakaway leaves it out of the ranking until the deal closes or ends. Its Quality Score is still shown.

From Pacira BioSciences' 8-K, Oct 8

PCRX's Quality Score fell 1 point on Fri, Nov 6, to 17. It did not trade higher than the day before.

Follow PCRX's trial news. Pro members can get an alert when Pacira BioSciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PCRX files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“Enrollment in Part A concluded in June, with topline data expected by the end of 2026.”Trial data · SEC filing · Aug 4

Why is PCRX up?

Up 73% in a year while the S&P 500 rose 11%.

“Net product sales of iovera° increased 6% in 2025 versus 2024 primarily due to a 7% increase in Smart Tip volume.”

Its fiscal 2025 10-K said

Sources: Price history, Nov 6, 2026; Annual report (10-K), Feb 26, 2026

1 more reason, free with an account →4 more reasons why PCRX beats the market, from its filings, with the company's words, the timeline, and its peers, for Pro members.

Key facts on PCRX

Key facts on PCRX
The chart	Its calmest 3 weeks in 6 months stronger than 96% of stocks
Latest filing	8-K, Oct 8 Signed a material agreement

1 more reason behind PCRX's 17, free with an account →3 more reasons behind PCRX's 17, for Pro members.

PCRX in the news

ReportThu Nov 5: the results are out. Past reports ›

Big story

Deal

Viatris to Acquire Pacira BioSciences for $1.65 Billion

PCRX closed +44.4% that day on 47.8x normal volume.

Reported by Yahoo Finance · covered by 18 outlets

Get an alert on PCRX's next big story →

Outlet counts from the GDELT Project. The move is what PCRX did that session, not a claim about why.

What's next

Expected to report Thu Feb 25, after the close

After its last 4 reports it closed -4.3% on average, higher 1 of 4 times.

PCRX catalysts

Coming up

34 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for PCRX

Next step the company has named

End of 2026“Enrollment in Part A concluded in June, with topline data expected by the end of 2026.”Trial data · SEC filing · Aug 4

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: ZILRETTA in Subjects With Shoulder OsteoarthritisPhase 3 · Active · 150 people · main data estimated Dec 2026 · NCT06269705

4 more trials, 1 with data due this year, 35 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

An officer, Lauren Riker, sold 6,000 shares on Oct 8, under a planned sale. 10 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Frank Lee buys or sells

For Pro members: every trade, and Frank Lee’s 5 filings and quotes.

Get an alert when PCRX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why PCRX scores 17

Excellentfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

+8Chart checks 8 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Persistence adds

No effect today: Size, Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on PCRX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:27 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when PCRX's Quality Score turns up

A free account. No card.

How PCRX ranks in Biotech

How PCRX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	PBLSParabilis Medicines		Open for its score
	PBYIPuma Biotechnology		Open for its score
	PCVXVaxcyte		Open for its score
	PDSBPDS Biotechnology		Open for its score
	PCRXPacira BioSciences	8/14	17

When does PCRX report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 108 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

-4.1%-10.0%+0.0%

Apr 30Aug 4Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	0.0%	+0.0%	not yet
Aug 4, 2026After close	After close	-5.7%	-10.0%	-11.7%
Apr 30, 2026After close	After close	+5.5%	-4.1%	-7.3%

PCRX closed higher after 1 of its last 4 reports.

All 4 reports, and PCRX's Quality Score going into each

PCRX sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $726M. It turned a profit in 2025 after a loss in 2024.

PCRX has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on PCRX, and all 14 on every stock.Get in free →

PCRX RSI on Nov 6: 83.2, above its 50-day and 200-day averages

Not scored

RSI 83.2, MACD below signal, above both averages. Not scored.13 readings

The deep dive on PCRX

What it does and how it makes money6 findings"As a result, we expect to receive $14.5 million from RDF, representing the royalties that we paid to RDF under protest after December 24, 2021 for EXPAREL made from the 45-liter manufacturing process." (10-K for fiscal 2025)SEC filing · Feb 26, 2026"We disagreed and explained that the royalty period under the agreement ended on December 24, 2021 with the expiration of our U.S. Patent No. 9,585,838." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
Where it stands3 findingsFor Pro members3 findings on where PCRX stands: its cash, debt, and share count, for Pro members
What changed in its filings7 findings"The Company filed a motion to dismiss the complaint, and in February 2026, the suit was dismissed with prejudice." (10-Q for the quarter to Jun 30, 2026)SEC filing · Aug 4, 2026A new heading in its "Risk Factors" this year: "Repurchases of our common stock may not result in increased stockholder value and could adversely affect our liquidity or financial flexibility." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 26, 2026, against the one of Feb 27, 2025Three Largest Customers made up 79% of its revenue in fiscal 2025, up from 77% in fiscal 2024; another made up 31%, down from 34% in fiscal 2024.SEC filing · Feb 26, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades PCRX, for Pro members

13 more findings on PCRX, each with its source, for Pro members.

PCRX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Frank D. LeeChief Executive Officer · no trades on file
Shawn CrossChief Financial Officer · 7 trades
Lauren RikerSenior Vice President, Finance · 4 trades
Jonathan SloninChief Medical Officer · 3 trades
Kristen WilliamsChief Administrative Officer · 2 trades
Brendan TeehanChief Commercial Officer · no trades on file
Mark FroimsonDirector · 1 trade
Alethia YoungDirector · no trades on file

5 more officers and directors file at PCRX.

See insider trades by person

Which ETFs hold PCRX?

In ETFs: PCRX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

829 employeesBrisbane, CApacira.com

What Pacira BioSciences says it competes with

“The pharmaceutical industry is intensely competitive and subject to rapid and significant technological change.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on PCRX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move PCRX's score: 4 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

See PCRX's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: PCRX's Quality Score is 17 (Excellent).

What does PCRX's Quality Score say?

PCRX scores 17 today, which Breakaway calls Excellent. It has 8 of 14 chart checks firing. Up 73% in a year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PCRX's Quality Score?

PCRX scores 17 today, which Breakaway calls Excellent (15 to 19). The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PCRX's 17.

When does PCRX report earnings?

Expected to report Thu Feb 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PCRX closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.